211 results on '"Gandemer, Virginie"'
Search Results
2. A software tool to support follow-up care in a French childhood cancer cohort: construction and feasibility
3. Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study
4. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients
5. Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials
6. Recent results of hematopoietic stem cell transplantation for thalassemia with busulfan-based conditioning regimen in France: improved thalassemia free survival despite frequent mixed chimerism. A retrospective study from the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)
7. Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group
8. Rôle de l’infirmière en pratique avancée (IPA) dans une unité de thérapie cellulaire : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
9. Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads
10. Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study
11. Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)
12. Prediction of success of CD34+ collection for autotransplantation in children
13. Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial
14. Que retenir dans la prise en charge des cancers en 2022 ?
15. Hypoxia regulates CD9 expression and dissemination of B lymphoblasts
16. Infections fongiques invasives chez l’enfant immunodéprimé en hématologie pédiatrique : recommandations de prise en charge au sein des centres de la SFCE
17. Conséquences d’un cancer dans l’enfance dans la quête du premier emploi dans l’interrégion Grand Ouest. Étude multiméthodes du groupe Grand Ouest Cancer de l’Enfant (GOCE) chez d’anciens patients et des professionnels
18. L’année 2021 dans tous ses états : une synthèse digérée
19. ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis
20. Hepatitis E Virus Infection in Pediatric Oncology
21. Therapeutic drug monitoring of imatinib:how far are we in the leukemia setting?
22. Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
23. A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
24. Impact of socioeconomic deprivation on time to diagnosis of childhood cancer
25. Treatment Duration and Complete Response (CR) in Adult and Pediatric Patients (Pts) Treated with Defibrotide (DF) for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT) in the Defifrance and EBMT PASS Registries
26. IMPACT de la déprivation sociale sur les difficultés psychosociales au décours d’un cancer pédiatrique : une étude prospective
27. Qu’est-ce que 2023 aura permis de changer dans nos pratiques en cancérologie ?
28. Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
29. Ovarian Function and Spontaneous Pregnancy After Hematopoietic Stem Cell Transplantation for Leukemia Before Puberty: An L.E.A. Cohort Study
30. The need for area under the curve measurements in the field of ganciclovir therapeutic drug monitoring in children: a case report
31. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
32. Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia
33. IMPACT of the Social Deprivation on Psychosocial Difficulties of Pediatric Cancer Survivors: A Prospective Study.
34. Interest of Cytoreductive Therapy before Allogenic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndromes: A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
35. Unrelated Cord Blood Transplantation in Children, Adolescents, and Young Adults with Acute Leukemia or Myelodysplastic Syndrome: A Retrospective Comparative Study from the French Society for Bone Marrow Transplantation and Cellular Therapy Between Real-World Data and Previously Reported Results of a Randomized Clinical Trial
36. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study
37. Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?
38. Educational outcomes in siblings of childhood leukemia survivors: Factors associated with school difficulties and comparison with general population.
39. Impact of childhood leukemia on siblings: their long-term perception of family functioning and its relationship with their psychosocial characteristics using structural equation modeling
40. The uterine volume is dramatically decreased after hematopoietic stem cell transplantation during childhood regardless of the conditioning regimen
41. Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL.
42. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
43. Supplementary Table from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
44. Data from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
45. Supplementary Figure from Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
46. Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL
47. Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort
48. Rôle de l’infirmière en pratique avancée (IPA) dans une unité de thérapie cellulaire : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
49. Outcomes of Defibrotide-Treated Patients (Pts) with Anicteric/Icteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Results from the Defifrance Registry Study
50. Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients (Pts) with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Pooled Analysis of Defifrance and EBMT PASS Registries
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.